Skip to content

Author

R. J. Keizer

3 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

Structured Evaluation of Model-Informed Precision Dosing of Mycophenolic Acid and Tacrolimus in Pediatric Patients with Kidney Disease.

Model-informed precision dosing-guided limited sampling strategies are feasible for estimation of current exposure using similar sampling times for mycophenolic acid and tacrolimus and accurate long-term prediction is not possible, underscoring the need for repeated therapeutic drug monitoring.

Astrid Heida, E. Cornelissen, R. Aarnoutse et al. · 0 citations
Open access Sep 2026

One Model to Dose Them All: A Population Pharmacokinetic Model for Multiple Aminoglycosides Across the Human Lifespan

Aminoglycosides require therapeutic drug monitoring due to substantial pharmacokinetic variability across individuals. While population pharmacokinetic (popPK) models have been developed for individual drugs across age groups, and cross‐drug maturation models have been explored, it is unclear whether pooling data acros...

Dominic M. H. Tong, Jonathan D. Faldasz, R. J. Keizer et al. · 0 citations
Review Open access Aug 2026

Pharmacokinetics of IL-23p19 Inhibitors: A Systematic Review Across Immune-Mediated Inflammatory Diseases

Interleukin (IL)-23p19 inhibitors are increasingly used in immune-mediated inflammatory diseases (IMIDs), particularly inflammatory bowel disease (IBD). Almost half of patients show inadequate response, partly due to pharmacokinetic (PK) variability. However, a comprehensive overview of their PK parameters is lacking,...

I. A. Pool, Alise D. E. de Groot, R. J. Keizer et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.